It is now widely acknowledged that larger platelets are biologically more active and express a greater prothrombotic potential, but there is no definitive evidence on the diagnostic accuracy role of mean platelet volume (MPV) in patients with ischemic heart disease. We performed an electronic search for articles that have assessed the diagnostic accuracy of MPV in patients admitted at the emergency department with a suspected diagnosis of ischemic heart disease, including articles in which the exact number of true-positive, false-positive, false-negative and true-negative test results could be either directly or indirectly extracted. Heterogeneity was assessed by I 2 test. The cumulative estimates and 95% confidence interval (95% CI) of sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), area under the receiver operator characteristic (ROC) curve (AUC) and diagnostic odds ratio (DOR) were calculated using a random effect model. Three studies were finally included in our analysis (mean quality score, 10.8) totaling 3577 participants (566 cases and 3011 controls). The between-study variation was high (I 2 , 96.2%; P < 0.001). The pooled estimates were 0.820 (95% CI 0.786-0.851) for sensitivity, 0.461 (95% CI 0.443-0.479) for specificity, 0.932 (95% CI 0.918-0.944) for NPV and 0.222 (95% CI 0.205-0.241) for PPV and 0.652 (95% CI 0.596-0.707) for AUC. The DOR was 3.9 (95% CI 2.3-6.5), with 0.52 diagnostic accuracy. The outcome of this meta-analysis suggests that MPV does not meet the requirements for efficient triage of patients in emergency department when used as standalone test, whereas its combination with high-sensitive troponin immunoassays merits further investigations. Blood Individual and pooled area under the receiver operating characteristic (ROC) curve (AUC) of studies assessing mean platelet volume on admission for diagnosing ischemic heart disease.
Introduction
Ischemic heart disease is the leading cause of death and disability worldwide, accounting for approximately one death every minute in the United States [1] . The most efficient approach for reducing mortality and disability in patients suffering from an acute myocardial infarction (AMI) entails an efficient and expedite diagnosis, as the positive outcome of reperfusion therapy is exceptionally time-dependent [2] . Although the assessment of cardiospecific troponin, either troponin T (TnT) or I (TnI), still represents the biochemical gold standard for diagnosing an acute coronary syndrome, the sensitivity and negative predictive value (NPV) of both TnT and TnI on patient admission at the emergency department (ED) are suboptimal, typically lower than 90% even when using the novel high-sensitive immunoassays [3] . Therefore, the introduction of additional parameters and/ or biomarkers, characterized by rapid turnaround time, low cost, high sensitivity and NPV is advisable to further improve the diagnostic efficiency of cardiospecific troponin testing and allow an efficient and fast clinical decision-making in frequently overcrowded EDs [4, 5] .
Due to the pivotal role played by platelets in the pathogenesis of coronary thrombosis, the evaluation of their indices represents a promising area of research, in which early and efficient biomarkers might be identified [6] . In a recent article published in this journal, Dogan et al. [7] convincingly showed that an increased mean platelet volume (MPV) was independently associated with non-ST-elevation myocardial infarction (NSTE-MI) presentation and severity of culprit stenosis, as well as with a greater 12-month risk of major cardiac outcomes. These findings are globally in agreement with those of a previous meta-analysis, including 16 cross-sectional studies and 2809 patients, in which Chu et al. [8] concluded that MPV was significantly higher in patients with AMI than in those without [mean increase, 0.92 fL; 95% confidence interval (CI) 0.67-1.16; P < 0.001]. The pooled results of three cohort studies including 3184 patients also showed that an increased MPV was associated with a higher risk of death as compared with a normal value (11.5 vs. 7.1%; odds ratio, 1.6; 95% CI 1.1-2.5; P ¼ 0.01). Finally, pooled results of five cohort studies including 430 patients undergoing coronary angioplasty showed that the MPV value was significantly increased in patients who developed restenosis than in those who did not (mean difference, 0.98 fL; 95% CI 0.74-1.21 fL; P < 0.001).
More than 30 years have occurred since the very first reliable report of a potential relationship between platelet size and ischemic heart disease was published by Martin et al. [9] . Since then, several other studies have confirmed the association between increased MPV and either presentation or prognosis of ischemic heart disease [8] , although the impact of this easy and relatively inexpensive parameter on the diagnostic approach of patients with suspected AMI has been largely neglected. Therefore, the aim of this study was to perform a systematic search and meta-analysis of scientific articles presenting data on the diagnostic accuracy of MPV in the setting of ischemic heart disease.
Search methodology
We performed an electronic search on PubMed, Thomson and Google Scholar, with no date restriction, for articles with a sample size greater than 25, which have assessed the diagnostic performance of MPV in patients admitted at the ED with a suspected diagnosis of ischemic heart disease. The following keywords were used: 'myocardial infarction' or 'ischemic heart disease' 'or 'acute coronary syndrome', in combination with 'mean platelet volume' or 'MPV' or 'platelet size'. The bibliographic references of articles published in English, French, Spanish and Italian were also reviewed for other pertinent investigations. All articles identified according to the search criteria were systematically revised for quality by two authors (G.L. and G.C.), according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist criteria [10] . Potential divergence was resolved by a third opinion (C.M.). After careful reading of abstract and text, only articles directly reporting the number of true-positive, false-positive, false-negative and true-negative test results, or those that allowed their calculation from sensitivity and specificity in combination with prevalence and sample size, were included in the meta-analysis. Heterogeneity was evaluated by x 2 -based statistics and I 2 test, wherein thresholds of 25, 50 and 75% designate low, moderate and high heterogeneity [11] . The cumulative estimates and 95% CI of sensitivity, specificity, NPV and positive predictive value (PPV) were then calculated using a random effect model for I 2 values greater than 50%. The area under the receiver operator characteristic (ROC) curve (AUC) values with 95% CI weighted for sample size were pooled according to Higgins et al. [11] . Statistical analysis was performed with MedCalc Version 12.3.0 (MedCalc Software, Mariakerke, Belgium).
Results
After exclusion of replicates across the databases, the electronic search identified 123 citations of studies and abstracts. One hundred and sixteen studies were Meta-analysis of platelet volume in heart disease Lippi et al. 217 Table 1 Diagnostic accuracy of mean platelet volume on admission for diagnosing ischemic heart disease excluded after title and abstract reading, because they did not assess MPV as a prognostic index or only compared MPV values between cases and controls, with no information on diagnostic accuracy of this parameter. The remaining seven studies were carefully assessed for quality after revision of full text, and three were excluded because they did not contain reliable information for calculating either the pooled AUC or the cumulative estimates of accuracy. One poster abstract was finally excluded due to the very limited sample size (21 patients overall, 10 cases and 11 controls). Interrater reliability was excellent (k ¼ 0.88; P < 0.001).
Overall, three studies could finally be included in our meta-analysis, all containing sufficient information for calculating the pooled diagnostic accuracy of MPV in patients with ischemic heart disease ( Table 1 ) [12] [13] [14] .
The sample size of the three studies (mean quality score, 10.8) totaled 3577 participants (566 cases and 3011 controls). The between-study variation was high and attributable to heterogeneity (x 2 , 78.52; DF, 3; I 2 , 96.2%; P < 0.001). Two studies involved a white population and were settled in two cities of northern Italy, whereas the remainder involved a Chinese population and was based in Taiwan. In all studies, the setting of patient admission was the ED, whereas the instrumentation used (Siemens Diagnostics, Deerfield, Illinois, USA; Beckman Coulter Inc, Brea, California, USA; Sismex Corporation, Kobe, Japan), as well as the cut-off of MPV (9.0, 7.5 and 10.65 fl), was remarkably different. The individual and pooled diagnostic accuracy of MPV is shown in Table 1 . The pooled estimates were 0.820 (95% CI 0.786-0.851) for sensitivity, 0.461 (95% CI 0.443-0.479) for specificity, 0.932 (95% CI 0.918-0.944) for NPV and 0.222 (95% CI 0.205-0.241) for PPV. The AUCs of the three single studies as well as the pooled AUC (0.652; 95% CI 0.596-0.707) are shown in Fig. 1 . Finally, the diagnostic odds ratio (DOR) was 3.9 (95% CI 2.3-6.5), with 0.52 diagnostic accuracy.
Discussion
The platelets actively participate in the pathogenesis of thrombosis, especially in the arterial circulation [15] . It is now widely acknowledged that larger platelets are biologically more active and express a greater prothrombotic potential, thereby representing an important risk factor for cardiovascular disease [8] . An increased MPV is also observed in a variety of clinical conditions that substantially increase the risk of ischemic heart disease, including aging [16] , hypertension [17] , metabolic syndrome [18] , as well as hypercholesterolemia [19] . The MPV has also been found as a strong, independent predictor of impaired angiographic reperfusion and 6-month mortality in acute ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention [20] .
Regardless of a causal or simply epidemiological association with cardiovascular disease, MPV has several aspects that would make it a promising, early biomarker of ischemic heart disease. First, it is virtually inexpensive, as it is part of the platelet indices that are automatically generated by the vast majority of modern hemocytometers within the complete blood count (CBC). Then, it is characterized by a very reduced turnaround time, which is inherently that of the CBC. Finally, MPV has been proven to be a highly sensitive and predictive biomarker in the context of ischemic heart disease, to be potentially used in combination with highly specific biomarkers, such as TnT and TnI. Despite the limited number of studies available and the broad heterogeneity, some conclusions can be drawn from the results of this meta-analysis. First, the excellent pooled sensitivity and NPV of the three studies (i.e. 0.820 and 0.932, respectively) support the concept that alteration in platelet size is indeed linked with the pathogenesis of ischemic heart disease, and reliably mirrors the presence of this condition at patient's admission to the ED. Although a large number of studies have assessed the value of MPV at presentation and for the prognosis of patients with ischemic heart disease [8] , only three of them have more carefully investigated the diagnostic accuracy of this biomarker in the early diagnosis of AMI, thus suggesting that further studies in which MPV is used as a stand-alone test or in combination with cardiospecific troponin immunoassays are needed to further refine the usefulness of this biomarker in the diagnostic approach of ischemic heart disease [12] [13] [14] . Finally, the high sensitivity of this biomarker is counterbalanced by very poor specificity and PPV (i.e. 0.461 and 0.222, respectively) for diagnosing ischemic heart disease at patient admission. As such, MPV does not meet the current requirements for an efficient triage of patients in the ED at least when used as a stand-alone test, whereas its combination with high-sensitive troponin immunoassays merits further scrutiny in larger studies. It is, in fact, noteworthy that the only study showing that the combination of MPV and troponin improved the sensitivity and overall diagnostic accuracy of the latter biomarker, has used a conventional troponin immunoassay, whereas most clinical laboratories are now shifting to high-sensitive methods.
